HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study.

AbstractBACKGROUND:
National Institutes of Health (NIH) category III prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent condition for which no standardised treatment exists.
OBJECTIVES:
To assess the safety and efficacy of a standardised pollen extract in men with inflammatory CP/CPPS.
DESIGN, SETTING, AND PARTICIPANTS:
We conducted a multicentre, prospective, randomised, double-blind, placebo-controlled phase 3 study comparing the pollen extract (Cernilton) to placebo in men with CP/CPPS (NIH IIIA) attending urologic centres.
INTERVENTION:
Participants were randomised to receive oral capsules of the pollen extract (two capsules q8h) or placebo for 12 wk.
MEASUREMENTS:
The primary endpoint of the study was symptomatic improvement in the pain domain of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). Participants were evaluated using the NIH-CPSI individual domains and total score, the number of leukocytes in post-prostatic massage urine (VB3), the International Prostate Symptom Score (IPSS), and the sexuality domain of a life satisfaction questionnaire at baseline and after 6 and 12 wk.
RESULTS AND LIMITATIONS:
In the intention-to-treat analysis, 139 men were randomly allocated to the pollen extract (n=70) or placebo (n=69). The individual domains pain (p=0.0086) and quality of life (QoL; p=0.0250) as well as the total NIH-CPSI score (p=0.0126) were significantly improved after 12 wk of treatment with pollen extract compared to placebo. Response, defined as a decrease of the NIH-CPSI total score by at least 25% or at least 6 points, was seen in the pollen extract versus placebo group in 70.6% and 50.0% (p=0.0141), respectively. Adverse events were minor in all patients studied.
CONCLUSIONS:
Compared to placebo, the pollen extract significantly improved total symptoms, pain, and QoL in patients with inflammatory CP/CPPS without severe side-effects.
AuthorsFlorian M E Wagenlehner, Henning Schneider, Martin Ludwig, Jörg Schnitker, Elmar Brähler, Wolfgang Weidner
JournalEuropean urology (Eur Urol) Vol. 56 Issue 3 Pg. 544-51 (Sep 2009) ISSN: 1873-7560 [Electronic] Switzerland
PMID19524353 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Plant Extracts
  • cernilton
Topics
  • Adolescent
  • Adult
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Phytotherapy
  • Plant Extracts (therapeutic use)
  • Prospective Studies
  • Prostatitis (drug therapy)
  • Secale
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: